- Daiichi Sankyo announced that Vanflyta (quizartinib) is now publicly reimbursed in Quebec following completion of pan-Canadian Pharmaceutical Alliance (pCPA) negotiations, enabling broader access discussions across Canada for adults with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML).
- The reimbursement covers Vanflyta use across induction, consolidation, and maintenance treatment phases, with or without transplant, following Health Canada approval granted in June 2025.
- Approval was supported by the Phase III QuANTUM-First trial, where Vanflyta combined with standard chemotherapy reduced the risk of death by 22.4% versus chemotherapy alone and extended median overall survival to 31.9 months compared with 15.1 months in the control arm.
- Vanflyta is a FLT3 inhibitor targeting FLT3-ITD mutations, which occur in approximately 25–30% of AML cases and are associated with aggressive disease, higher relapse risk, and poorer survival outcomes.
Takeaways:
Quaebec’s reimbursement of Vanflyta is a pivotal step toward pan‑Canadian access for a high‑value, biomarker‑targeted AML therapy.
Market-wise, public funding across induction, consolidation, and maintenance settings should drive near‑term adoption among newly diagnosed FLT3‑ITD AML patients (25–30% of AML) and position quizartinib as a standard-of-care partner to chemotherapy, especially given the 22.4% mortality reduction and doubling of median overall survival (31.9 vs 15.1 months) in the QuANTUM‑First trial.
Source: CA Newswire
